UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

hours per response... 0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person * Ainsworth Sean				2. Issuer Name and Ticker or Trading Symbol Ocuphire Pharma, Inc. [OCUP]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director						
(Last) (First) (Middle) C/O OCUPHIRE PHARMA, INC., 37000 GRAND RIVER AVE, SUITE 120				3. Date of Earliest Transaction (Month/Day/Year) 11/19/2020								_	Office	r (give	title below)	Oth	er (specify belo	w)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person						
		ILLS, MI 48335														48		
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							Acquire	ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Yea	2A. Deemed Execution Date, if any (Month/Day/Year)		te, if ((Instr. 8)		(A (In	4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)		f (D) O Ti	Owned Follow Transaction(s) (Instr. 3 and 4)		· .		Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
C							Code P			nount	(D)	Price	11.665				(Instr. 4)	
Common	Stock		11/19/2020			- 1		8,	865	A	(1) 4	44,665			D			
	,		3A. Deemed Execution Date, if	4. 5. Numl Transaction of Deriv Code Securiti			a currently val			id OMB or Benefi e securit	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of	of 10. Owners Form of Derivat Security Direct (or Indir	Ownersh (Instr. 4) D) ect		
				Code	V	(A)		Date Exercis	sable	Expir Date	ation	Title	or	ount nber res		(msu. 4)	(msu. 4	,
Series A Warrant (right to buy)	\$ 4.4795 (2)	11/19/2020		Р	13	,394		11/19	/2020	11/1	9/2025	Comm	. 11.5.	394	(1)	13,394	D	
Series B Warrant (right to buy)	\$ 0.0001	11/19/2020		P		,574 (2)		11/19	/2020	01/2	8/2022	Comm	1.1.1	574	(1)	1,574	D	
Repor	ting O	wners																

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Ainsworth Sean							
C/O OCUPHIRE PHARMA, INC.	X						
37000 GRAND RIVER AVE, SUITE 120	Λ						
FARMINGTON HILLS, MI 48335							

Signatures

/s/ Emily J. Johns, by Power of Attorney	11/25/2020			
**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of \$50,000.
- (2) Subject to adjustment based on certain price reset provisions.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.